

Main Article

Luigi Angelo Vaira takes responsibility for the integrity of the content of this paper

Cite this article: Vaira LA *et al.* Olfactory recovery following omicron variant infection: a psychophysical prospective case–control study with six-month follow up. *J Laryngol Otol* 2023; **137**:1395–1400. <https://doi.org/10.1017/S0022215123000877>

Received: 1 March 2023

Revised: 5 April 2023

Accepted: 29 April 2023

First published online: 17 May 2023




Keywords:

Anosmia; ageusia; Covid-19; smell; SARS-CoV-2; coronavirus; taste; otolaryngology

Corresponding author:

Luigi Angelo Vaira;
Email: lavaira@uniss.it

Olfactory recovery following omicron variant infection: a psychophysical prospective case–control study with six-month follow up

Luigi Angelo Vaira^{1,2} , Paolo Boscolo-Rizzo³, Jerome R Lechien^{4,5} , Miguel Mayo-Yáñez⁶ , Marzia Petrocelli^{1,7}, Laura Pistidda⁸, Giovanni Salzano^{1,9}, Fabio Maglitto^{1,9}, Claire Hopkins^{10,11} and Giacomo De Riu¹

¹Maxillofacial Surgery Operative Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ²Biomedical Science Department, School of Biomedical Science, University of Sassari, Sassari, Italy, ³Department of Medical, Surgical and Health Sciences, Section of Otolaryngology, University of Trieste, Trieste, Italy, ⁴Department of Anatomy and Experimental Oncology, Mons School of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons, Mons, Belgium, ⁵Department of Otolaryngology – Head Neck Surgery, Elsan Polyclinic of Poitiers, Poitiers, France, ⁶Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Complex of A Coruña ('CHUAC'), A Coruña, Spain, ⁷Maxillofacial Surgery Unit, Bellaria-Maggiore Hospital, Azienda Unità Sanitaria Locale della ('AUSL') Bologna, Bologna, Italy, ⁸Intensive Care Unit Operative Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, ⁹Department of Maxillofacial Surgery, University of Naples 'Federico II', Naples, Italy, ¹⁰Rhinology, King's College, London, UK and ¹¹British Rhinological Society, London, UK

Abstract

Objective. This study aimed to evaluate the recovery of olfactory function at six months in individuals infected with the coronavirus disease 2019 omicron variant, using psychophysical tests.

Methods. A prospective case–control study that included severe acute respiratory syndrome coronavirus-2 patients infected in February and March 2022 was conducted. Patients underwent the Sniffin' Sticks test within 10 days of infection and again after at least 6 months. The olfactory scores were compared with those of a control group.

Results. In all, 102 patients and 120 controls were enrolled in the study. At baseline, 26 patients (25.5 per cent) self-reported smell loss. The median threshold, discrimination and identification score was 33.6 (interquartile range, 12.5) for the cases and 36.5 (interquartile range, 4.38) for the controls ($p < 0.001$). Based on the threshold, discrimination and identification scores, 12 controls and 34 patients reported olfactory dysfunction ($p < 0.001$). Eighty cases underwent re-evaluation at six months; the median threshold, discrimination and identification score was 37.1 (interquartile range, 4.75) with no significant differences compared with the controls.

Conclusion. Six months after infection, the prevalence of olfactory dysfunction in patients did not differ significantly from the control population.

Introduction

Persistent olfactory dysfunction represents a frequent symptom of long coronavirus disease 2019 (Covid-19), affecting 5–30 per cent of the individuals one year after severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection.^{1–5} Given this high prevalence and the devastating effects on patients' quality of life,^{6,7} persistent olfactory dysfunction has become a healthcare challenge.⁸

Fortunately, it appears that the prevalence of olfactory dysfunction as a result of infection has decreased over time, from over 50 per cent in the early pandemic waves^{9,10} to 1–30 per cent in those with Covid-19 caused by the omicron variant.^{11–13} However, to date no studies have assessed whether this lower prevalence corresponds to a lower frequency of persistent olfactory dysfunction.

This study aimed to evaluate by psychophysical tests the recovery of olfactory function at six months in individuals infected with the omicron variant.

Materials and methods

This prospective case–control study was conducted at the University Hospital of Sassari from February to October 2022. The study protocol was approved by the ethics committee of the University Hospital of Cagliari (ethical approval code: PG 2021/7118) and written informed consent was obtained from each participant.

The study included patients with a confirmed diagnosis of SARS-CoV-2 infection in February and March 2022. During this period, the omicron variant had a prevalence of over 98 per cent in the Sardinia region for more than two weeks.¹⁴ In order to reduce the risk of inclusion bias, patients were enrolled consecutively using the lists of individuals

with positive infection results as provided by the Department of Prevention of the University Hospital of Sassari. Furthermore, a group of healthy individuals who had never been diagnosed with SARS-CoV-2 infection were included as controls. All these individuals were part of the hospital staff and therefore subjected to frequent checks with swabs and serological tests, with consistently negative results.

The exclusion criteria for both groups were: (1) previous Covid-19; (2) history of olfactory dysfunction; (3) previous surgery, radiotherapy or trauma to the nasal cavity; (4) chronic rhinosinusitis with and without nasal polyps; (5) neurological or psychiatric co-morbidities; and (6) age less than 18 years. Some of the patients and control participants were included in a previous study on the prevalence of olfactory dysfunction during omicron variant infection.¹²

Data collection

Some general data were collected for all enrolled individuals, including age, gender and vaccination status. Self-reported olfactory loss was investigated using the specific entry of the Covid-19 symptom index, which classifies olfactory function as normal, reduced or completely abolished.¹⁵ Evaluation of olfactory function was performed through the extended version of the Sniffin' Sticks test according to the administration protocol previously described.^{16,17} The Sniffin' Sticks test evaluates three domains of olfactory function: threshold, discrimination and identification. Each of these functions is assigned a variable score of 1–16 for threshold and 0–16 for discrimination and identification. The sum of these scores leads to an overall threshold, discrimination and identification score that categorises olfactory function as normosmia (threshold, discrimination and identification score of ≥ 31), hyposmia (threshold, discrimination and identification score of 17–30.75) or anosmia (threshold, discrimination and identification score of < 17). The evaluation took place within 10 days of the diagnosis of infection in the case group.

All the cases were re-evaluated in the same way at least six months after the first evaluation. Patients were excluded from re-evaluation if they contracted the infection during the follow-up period.

Statistical analysis

Statistical analyses were performed using jamovi version 2.3.18.0, a freeware and open statistical software for desktop computers and 'the cloud' servers.¹⁸ Categorical variables are reported in numerals and percentages of the total. Descriptive statistics for quantitative variables are given as the median (interquartile range). For the purposes of the statistical analysis, patients were classified into three categories of olfactory function according to the psychophysical scores obtained: normal, hyposmic and anosmic. A chi-square test was performed to evaluate the differences between cases and controls in terms of proportions of normal, hyposmic and anosmic individuals. Analysis of the differences between the Sniffin' Sticks test results at baseline and at six months was performed by the Wilcoxon signed rank test. Differences in the Sniffin' Sticks test results between groups was assessed with the Mann-Whitney U test. The level of statistical significance was set at $p < 0.05$, with a 95 per cent confidence interval. Sample size was calculated using the 'jpower' module of the jamovi software. Considering a minimally interesting effect size of

0.5, a power of 80 per cent and a 5 per cent margin of error, the calculated minimum sample size for each group was 64 individuals.

Results

In all, 102 patients and 120 controls who met the inclusion and exclusion criteria were enrolled in the study. The case group consisted of 49 women and 53 men with a median age of 45 years (interquartile age range, 11 years) and a vaccination rate of 99 per cent. The control group consisted of 61 women and 51 men with a median age of 44 years (interquartile age range, 8 years) and a vaccination rate of 100 per cent. The two groups were homogeneous for gender ($p = 0.678$), age ($p = 0.229$) and vaccination rate ($p = 1$).

At baseline in the case group, 10 (9.8 per cent) and 16 (15.7 per cent) patients reported a complete or partial loss of smell, respectively. For the psychophysical tests, the median threshold, discrimination and identification score was 33.6 (interquartile range, 12.5) for the cases and 36.5 (interquartile range, 4.38) for the controls, with a statistically significant difference between the two groups ($p < 0.001$) (Figure 1). Based on the threshold, discrimination and identification scores, 12 of the 120 (10 per cent) controls had hyposmia; in contrast, 34 of the 102 (33.3 per cent) patients in the case group reported an olfactory dysfunction, including 16 cases (15.7 per cent) of anosmia and 18 cases (17.6 per cent) of hyposmia (Figure 2). The differences between the two groups were statistically significant ($p < 0.001$).

Re-evaluation was carried out at least six months later (range, 180–212 days) on 80 patients from the case group (78 per cent); 9 patients were excluded, including 8 who developed a second infection and 1 who suffered a nasal fracture during the follow-up period, and 13 patients did not attend for re-evaluation. The two groups were still homogeneous for gender ($p = 0.908$), age ($p = 0.803$) and vaccination rate ($p = 1$). In the case group, four patients (5 per cent) self-reported persistent hyposmia, associated in two cases with mild parosmia. With psychophysical testing, the median threshold, discrimination and identification score was 37.1 (interquartile range, 4.75) for cases, with no statistically




Figure 1. Comparison of baseline threshold, discrimination and identification (TDI) scores between the case group and control group. Circles indicate individual data points. The boxes span 25th–75th percentiles, with the horizontal lines representing the median, the whiskers indicating the 95 per cent confidence interval, and the curved lines reflecting the distribution of the data points.




Figure 2. Comparison of clinical diagnosis of olfactory function between the case group and control group at baseline.

significant differences between the two groups (37.1 vs 36.5; $p = 0.580$) (Figure 3). Changes in the threshold, discrimination and identification score of the case group over time were statistically significant ($p < 0.001$). Based on the threshold, discrimination and identification scores, nine patients (11.3 per cent) had olfactory dysfunction, including eight cases (10 per cent) of hyposmia and one case (1.3 per cent) of anosmia (Figure 4). The difference between the two groups was not statistically significant ($p = 0.470$).

Discussion

Since the beginning of the pandemic, SARS-CoV-2 has undergone numerous mutations that have led to a succession of variants of concern. The omicron variant made its appearance in South Africa in October 2021.¹⁹ As a result of its high contagiousness, the omicron variant spread rapidly around the world becoming the predominant variant of concern at the end of January 2022.²⁰ Similarly, the characteristics of the general population have changed over time due to immunisation obtained with vaccination or with previous infection. It is therefore unsurprising that the clinical picture of Covid-19 has changed over time.²¹

During the pandemic, there was a gradual reduction in the prevalence of olfactory dysfunction,^{22,23} with a significant difference comparing the omicron variant with the first pandemic waves.^{11–13} In this study, 25.5 per cent of patients self-reported




Figure 3. Comparison of six-month threshold, discrimination and identification (TDI) scores between the case group and control group. Circles indicate individual data points. The boxes span 25th–75th percentiles, with the horizontal lines representing the median, the whiskers indicating the 95 per cent confidence interval, and the curved lines reflecting the distribution of the data points.

a loss of smell during infection, and 33.3 per cent had threshold, discrimination and identification scores indicative of olfactory dysfunction. This prevalence is significantly lower than that recorded in the Sardinia region itself during the first pandemic waves, which exceeded 70 per cent.^{24–26} However, impairment of olfactory function still affects more than one-third of patients and therefore remains an important symptom to be considered in order to suspect SARS-CoV-2 infection.

The reasons behind the reduced ability of the omicron variant to induce olfactory dysfunction are not yet fully understood. In fact, the omicron variant presents the D614 G mutation of the spike protein, which has been associated in the past with a higher incidence of olfactory dysfunction.²⁷ It is therefore possible that the lower olfactory dysfunction rate is due to the fact that the omicron variant diffuses less easily in the nasal mucus²⁸ and that it uses transmembrane serine protease 2 less effectively as an access route into the olfactory epithelium cells.^{28,29} On the other hand, it is possible that the more effective response in immunised subjects leads to a more rapid viral wash out before this can induce sufficient damage to cause clinically evident olfactory dysfunction.^{30,31} However, it is likely that both of these factors are implicated, because olfactory dysfunction has been found to be frequent with previous variants of concern, even in already immunised subjects.^{32,33}

The very high number of patients with Covid-19 who self-reported persistent olfactory dysfunction represents a major challenge. A recent meta-analysis³ estimated that 5.6 per cent of patients self-reported a persistent olfactory disorder six months after Covid-19, with the prevalence rising to over 30 per cent when evaluated with psychophysical tests.³⁴ Persistent olfactory dysfunction has a devastating effect on the quality of life of patients, who may isolate themselves socially, reduce their work productivity and withdraw from normal daily activities.^{6,7,35} For these reasons, persistent olfactory dysfunction represents an unprecedented health challenge.^{8,36–38}

To the best of our knowledge, the recovery rate of olfactory function after omicron variant infection has not yet been investigated. The assessment of olfactory recovery should include psychophysical tests because patients often tend to overestimate recovery, especially if they present with complete anosmia at baseline,^{1,34} and the follow up should be long enough to detect delayed recoveries that are significantly frequent in the first three months after infection.³⁹ In this study, the prevalence of




Figure 4. Comparison of clinical diagnosis of olfactory function between the case group and control group at the six-month follow up.

persistent olfactory dysfunction was 11.3 per cent, with only one case of anosmia. The differences between the cases and the controls were not significant either for the threshold, discrimination and identification score or for the clinical classifications of olfactory function. In the pandemic waves caused by previous variants of concern, several authors found a six-month rate of complete anosmia of around 10 per cent, exceeding 25 per cent if we consider the hyposmic subjects.^{39–43}

- Olfactory dysfunction prevalence from infection decreased from over 50 per cent in early pandemic waves to 1–30 per cent during coronavirus disease 2019 caused by the omicron variant
- No studies have assessed whether this lower prevalence corresponds to a lower frequency of persistent olfactory dysfunction
- In this study, omicron variant infection was associated with a significantly lower persistent olfactory dysfunction rate than previous variants
- At six months, the prevalence of olfactory dysfunction in infected patients did not differ significantly from the general population

The pathogenetic mechanism and risk factors underlying the persistence of olfactory dysfunction in some individuals have not been established with certainty.^{44–46} It has been hypothesised that the damage to the olfactory epithelium during infection is so severe and extensive in some individuals that it causes the loss of basal cells, which are necessary for

the epithelium to regenerate.^{47–49} In this sense, the omicron variant has been shown not to cause such severe damage to the olfactory epithelium as previous variants of concern⁵⁰ and it does not appear to have neuroinvasive capabilities.^{50,51} Moreover, a high concentration of nasal immunoglobulins was detected as a protective factor for the development of persistent olfactory dysfunction.^{52,53} Vaccinated subjects have been shown to have higher levels of nasal and salivary secretory immunoglobulins compared to post-infection immunised individuals, especially after the second dose.^{31,54}

Finally, another reason for this improved long-term outcome may be related to the fact that all patients included in this study were initiated early on a therapeutic protocol of olfactory training associated with palmitoylethanolamide and luteolin supplementation.⁵⁵ Several authors have demonstrated the effectiveness of olfactory training in promoting and speeding up the recovery of olfactory function after SARS-CoV-2 infection.^{56–59} However, in our opinion, it is important to closely monitor patients with olfactory dysfunction during infection, starting them with olfactory training early for at least two reasons. Firstly, in this study, 5 per cent of patients still self-reported incomplete recovery at six months. Secondly, the 60-day re-evaluation of controls who developed infection in the follow-up period found that although threshold, discrimination and identification scores returned to levels that classified individuals as normosmic, median *T* values were significantly lower than before infection.⁶⁰ This olfactory alteration, although unconscious and therefore not affecting quality of life, can expose patients to environmental dangers.

This study has some limitations that need to be acknowledged. Firstly, although patient enrolment occurred when omicron variant circulation was greater than 98 per cent for more than two weeks, variant of concern determination was not performed and contamination may have occurred. Secondly, to reduce the risk of selection bias, patients were enrolled consecutively from lists provided by the Department of Prevention of the University Hospital of Sassari, and it was not initially disclosed that the test would involve smell. It is possible that patients with more severe symptoms were more likely to agree to evaluation, as well as individuals with self-perceived olfactory dysfunction at baseline agreeing to undergo re-evaluation at six months. Thirdly, the controls were not tested for SARS-CoV-2 infection at the time of olfactory evaluation. However, the individuals included in the control group were part of the hospital staff and then subjected to regular antigenic swabs and immunoglobulin assays, which were consistently negative. Fourthly, the six-month follow up is not long enough to rule out late recoveries that can occur spontaneously, even two years after infection.⁶¹

Conclusion

Based on the results of the present study, patients infected with the Covid-19 omicron variant appear to exhibit a significantly lower persistent olfactory dysfunction rate than with previous Covid-19 variants. At six months, the prevalence of olfactory dysfunction in patients who had been infected did not differ significantly from the general population.

Competing interests. None declared.

References

- 1 Vaira LA, Salzano G, Le Bon S, Maglio A, Petrocelli M, Steffens Y *et al.* Prevalence of persistent olfactory disorders in patients with COVID-19:

- a psychophysical case-control study with 1-year follow-up. *Otolaryngol Head Neck Surg* 2022;**167**:183–6
- 2 Boscolo-Rizzo P, Guida F, Polesel J, Marcuzzo AV, Antonucci P, Capriotti V *et al.* Self-reported smell and taste recovery in coronavirus disease 2019 patients: a one-year prospective study. *Eur Arch Otorhinolaryngol* 2022;**279**:515–20
 - 3 Tan BKJ, Han R, Zhao JJ, Tan NKW, Quah ESH, Tan CJ *et al.* Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. *BMJ* 2022;**378**:e069503
 - 4 Lechien JR, Vaira LA, Saussez S. Prevalence and 24-month recovery of olfactory dysfunction in COVID-19 patients: a multicentre prospective study. *J Intern Med* 2023;**293**:82–90
 - 5 Boscolo-Rizzo P, Hummel T, Invitto S, Spinato G, Tomasoni M, Emanuelli E *et al.* Psychophysical assessment of olfactory and gustatory function in post-mild COVID-19 patients: a matched case-control study with two-year follow-up. *Int Forum Allergy Rhinol* 2023. Epub 2023 Feb 28
 - 6 Vaira LA, Gessa C, Deiana G, Salzano G, Maglitter F, Lechien JR *et al.* The effects of persistent olfactory and gustatory dysfunctions on quality of life in long-COVID-19 patients. *Life (Basel)* 2022;**12**:141
 - 7 Saniasaya J, Prepageran N. Impact of olfactory dysfunction on quality of life in coronavirus disease 2019 patients: a systematic review. *J Laryngol Otol* 2021;**135**:947–52
 - 8 Boscolo-Rizzo P, Polesel J, Vaira LA. Smell and taste dysfunction after covid-19. *BMJ* 2022;**378**:o1653
 - 9 Saniasaya J, Islam MA, Abdullah B. Prevalence of olfactory dysfunction in coronavirus disease 2019 (COVID-19): a meta-analysis of 27,492 patients. *Laryngoscope* 2021;**131**:865–78
 - 10 Vaira LA, Lechien JR, Khalife M, Petrocelli M, Hans S, Distinguin L *et al.* Psychophysical evaluation of the olfactory function: European multicenter study on 774 COVID-19 patients. *Pathogens* 2021;**10**:62
 - 11 Boscolo-Rizzo P, Tirelli G, Meloni P, Hopkins C, Madeddu G, De Vito A *et al.* Coronavirus disease 2019 (COVID-19)-related smell and taste impairment with widespread diffusion of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) omicron variant. *Int Forum Allergy Rhinol* 2022;**12**:1273–81
 - 12 Vaira LA, Lechien JR, Deiana G, Salzano G, Maglitter F, Piombino P *et al.* Prevalence of olfactory dysfunction in D614G, alpha, delta and omicron waves: a psychophysical case-control study. *Rhinology* 2023;**61**:32–8
 - 13 Cardoso CC, Rossi AD, Galliez RM, Faffe DS, Tanuri A, Castineiras TMPP. Olfactory dysfunction in patients with mild COVID-19 during gamma, delta and omicron waves in Rio de Janeiro, Brazil. *JAMA* 2022;**328**:582–3
 - 14 Overview of Variants in Countries. In: <https://covariants.org/per-country> [25 August 2022]
 - 15 Lechien JR, Chiesa-Estomba CM, Hans S, Calvo-Henriquez C, Mayo-Yanez M, Tucciarone M *et al.* Validity and reliability of the COVID-19 symptom index, an instrument evaluating severity of general and otolaryngological symptoms. *Acta Otolaryngol* 2021;**141**:615–20
 - 16 Hummel T, Kobal G, Gudziol H, Mackay-Sim A. Normative data for the “Sniffin’ Sticks” including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects. *Eur Arch Otorhinolaryngol* 2007;**264**:237–43
 - 17 Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. ‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. *Chem Senses* 1997;**22**:39–52
 - 18 The jamovi project, Version 2.3 [computer software]. Jamovi: Sydney, 2022. In: <http://jamovi.org>
 - 19 World Health Organization. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. In: [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern) [2 November 2022]
 - 20 Boscolo-Rizzo P, Hummel T, Hopkins C, D’Alessandro A, Menini A, Dibattista M *et al.* Comprehensive chemosensory psychophysical evaluation of self-reported gustatory dysfunction in patients with long-term COVID-19: a cross-sectional study. *JAMA Otolaryngol Head Neck Surg* 2022;**148**:281–2
 - 21 Maisa A, Spacciferri G, Fournier L, Schaeffer J, Deniau J, Rolland P *et al.* First cases of omicron in France are exhibiting mild symptoms, November 2021–January 2022. *Infect Dis Now* 2022;**52**:160–4
 - 22 Klimek L, Hagemann J, Hummel T, Altundag A, Hintschich C, Stielow S *et al.* Olfactory dysfunction is more severe in wild-type SARS-CoV-2 infection than in the Delta variant (B.1.617.2). *World Allergy Organ J* 2022;**15**:100653
 - 23 Hintschich CA, Vielsmeier V, Bohr C, Hagemann J, Klimek L. Prevalence of acute olfactory dysfunction differs between variants of SARS-CoV-2—results from chemosensitive testing in wild type, VOC alpha (B.1.1.7) and VOC delta (B.1.617.2). *Eur Arch Otorhinolaryngol* 2022;**279**:5445–7
 - 24 Vaira LA, De Vito A, Deiana G, Pes C, Giovanditto F, Fiore V *et al.* Correlations between IL-6 serum level and olfactory dysfunction severity in COVID-19 patients: a preliminary study. *Eur Arch Otorhinolaryngol* 2021;**279**:811–16
 - 25 Vaira LA, Deiana G, Lechien JR, De Vito A, Cossu A, Dettori M *et al.* Correlations between olfactory psychophysical scores and SARS-CoV-2 viral load in COVID-19 patients. *Laryngoscope* 2021;**131**:2312–18
 - 26 Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A *et al.* Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. *Head Neck* 2020;**42**:1252–8
 - 27 von Bartheld CS, Mathew D, Butowt R. New study on prevalence of anosmia in COVID-19 implicates the D614 G virus mutation as a major contributing factor to chemosensory dysfunction. *Eur Arch Otorhinolaryngol* 2021;**278**:3593–4
 - 28 Butowt R, Bilinska K, von Bartheld C. Why does the omicron variant largely spare olfactory function? Implications for the pathogenesis of anosmia in coronavirus disease 2019. *J Infect Dis* 2022;**226**:1304–8
 - 29 Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I *et al.* Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts infectivity and fusogenicity. *Nature* 2022;**603**:706–14
 - 30 Vaira LA, Lechien JR, Salzano G, Maglitter F, Saussez S, De Riu G. The role of nasal immunoglobulins in the recovery of olfactory function in COVID-19 patients. *Am J Otolaryngol* 2022;**43**:103301
 - 31 Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y *et al.* Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. *Mucosal Immunol* 2022;**15**:799–808
 - 32 Lechien JR, Chiesa-Estomba CM, Radulesco T, Michel J, Caira LA, Le Bon SD *et al.* Clinical features of patients who had two COVID-19 episodes: a European multicentre case series. *J Intern Med* 2021;**290**:421–9
 - 33 Vaira LA, De Vito A, Lechien JR, Chiesa-Estomba CM, Mayo-Yañez M, Calvo-Henriquez C *et al.* New onset of smell and taste loss are common findings also in patients with symptomatic COVID-19 after complete vaccination. *Laryngoscope* 2022;**132**:419–21
 - 34 Boscolo-Rizzo P, Hummel T, Hopkins C, Dibattista M, Menini A, Spinago G *et al.* High prevalence of long-term olfactory, gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation. *Rhinology* 2021;**59**:517–27
 - 35 Boesveldt S, Parma V. The importance of the olfactory system in human well-being, through nutrition and social behaviour. *Cell Tissue Res* 2021;**383**:559–67
 - 36 Vaira LA, De Riu G, Salzano G, Maglitter F, Boscolo-Rizzo P, Lechien JR. COVID-19 related persistent olfactory disorders represent an unprecedented challenge. *Am J Otolaryngol* 2022;**44**:103667
 - 37 Tan NKW, Tan CJ, Tan BKJ, Han R, Zhao JJ, Quah ESH *et al.* The burden of prolonged smell and taste loss in covid-19. *BMJ* 2022;**378**:o1895
 - 38 Lechner M, Liu J, Counsell N, Gillespie D, Chandrasekharan D, Ta NH *et al.* The burden of olfactory dysfunction during the COVID-19 pandemic in the United Kingdom. *Rhinology* 2023;**61**:93–6
 - 39 Petrocelli M, Cutrupi S, Salzano G, Maglitter F, Salzano FA, Lechien JR *et al.* Six-month smell and taste recovery rates in coronavirus disease 2019 patients: a prospective psychophysical study. *J Laryngol Otol* 2021;**135**:436–41
 - 40 Hopkins C, Surda P, Vaira LA, Lechien JR, Safarian M, Saussez S *et al.* Six month follow-up of self-reported loss of smell during the COVID-19 pandemic. *Rhinology* 2021;**59**:26–31
 - 41 Riestra-Ayora J, Yanes-Diaz J, Esteban-Sanchez J, Vaduva C, Molina-Quiros C, Larrano-Jimenez A *et al.* Long-term follow-up of olfactory and gustatory dysfunction in COVID-19: 6 months case-control study of health workers. *Eur Arch Otorhinolaryngol* 2021;**278**:4831–7
 - 42 Teaima AA, Salem OM, Teaima MAEM, Mansour OI, Taha MS, Bard FM *et al.* Patterns and clinical outcomes of olfactory and gustatory disorders in six months: prospective study of 1031 COVID-19 patients. *Am J Otolaryngol* 2022;**43**:103259
 - 43 Boscolo-Rizzo P, Menegaldo A, Fabbris C, Spinato G, Borsetto D, Vaira LA *et al.* Six-month psychophysical evaluation of olfactory dysfunction in patients with COVID-19. *Chem Senses* 2021;**46**:bjab006

- 44 Paderno A, Schreiber A, Grammatica A, Raffetti E, Tomasoni M, Gualtieri T *et al.* Smell and taste alterations in COVID-19: a cross-sectional analysis of different cohorts. *Int Forum Allergy Rhinol* 2020;**10**:955–62
- 45 Chary E, Carsuzaa F, Trijolet JP, Capitaine AL, Roncato-Saberan M, Fouet K *et al.* Prevalence and recovery from olfactory and gustatory dysfunctions in Covid-19 infection: a prospective multicenter study. *Am J Rhinol Allergy* 2020;**34**:686–93
- 46 Amadu AM, Vaira LA, Lechien JR, Scaglione M, Saba L, Lampus ML *et al.* Analysis of the correlations between the severity of lung involvement and olfactory psychophysical scores in coronavirus disease 2019 (COVID-19) patients. *Int Forum Allergy Rhinol* 2022;**12**:103–7
- 47 Dias de Melo G, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F *et al.* COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. *Sci Transl Med* 2021;**13**:eabf8396
- 48 Khan M, Yoo SJ, Clijsters M, Backaert W, Vanstapel A, Speleman K *et al.* Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb. *Cell* 2021;**184**:5932–49
- 49 Vaira LA, Hopkins C, Sandison A, Manca A, Machouchas N, Turilli D *et al.* Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. *J Laryngol Otol* 2020;**134**:1123–7
- 50 Armando F, Beythien G, Kaiser FK, Allnoch L, Heydemann L, Rosiak M *et al.* SARS-CoV-2 omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. *Nat Commun* 2022;**13**:3519
- 51 Bauer L, Rissmann M, Benavides FFW, Leijten L, van Run P, Begeman L *et al.* In vitro and in vivo differences in neurovirulence between D614G, delta and omicron BA.1 SARS-Cov-2 variants. *Acta Neuropathol Commun* 2022;**10**:124
- 52 Saussez S, Sharma S, Thiriard A, Olislagers V, Vu Duc I, Le Bon SD *et al.* Predictive factors of smell recovery in a clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction. *Eur J Neurol* 2021;**28**:3702–11
- 53 Vaira LA, De Riu G, Mayo-Yañez M, Gengler IM, Lechien JR. Prevalence of chemosensitive disorders with omicron infections and the possible impacts of vaccination. *Int J Infect Dis* 2023;**129**:205–6
- 54 Guerrieri M, Francavilla B, Fiorelli D, Nuccetelli M, Passali FM, Coppeta L *et al.* Nasal and salivary mucosal humoral immune response elicited by mRNA BNT162b2 COVID-19 vaccine compared to SARS-CoV-2 natural infection. *Vaccines (Basel)* 2021;**9**:1499
- 55 Di Stadio A, D’Ascanio L, Vaira LA, Cantone E, De Luca P, Cingolani C *et al.* Ultramicrozoned palmitoylethanolamide and luteolin supplement combined with olfactory training to treat post-COVID-19 olfactory impairment: a multicenter double-blinded randomized placebo-controlled clinical trial. *Curr Neuropharmacol* 2022;**20**:2001–12
- 56 Altundag A, Ylmaz E, Kesimli MC. Modified olfactory training is an effective treatment method for COVID-19 induced parosmia. *Laryngoscope* 2022;**132**:1433–8
- 57 Kattar N, Do TM, Unis GD, Migneron MR, Thomas AJ, McCoul ED. Olfactory training for postviral olfactory dysfunction: systematic review and meta-analysis. *Otolaryngol Head Neck Surg* 2021;**164**:244–54
- 58 Lechien JR, Vaira LA, Saussez S. Effectiveness of olfactory training in COVID-19 patients with olfactory dysfunction: a prospective study. *Eur Arch Otolaryngol* 2023;**280**:1255–63
- 59 Asvapoositkul V, Samuthopongtorn J, Aeumjaturapat S, Snidvongs K, Chusakul S, Seresirikachorn K *et al.* Therapeutic options of post-COVID-19 related olfactory dysfunction: a systematic review and meta-analysis. *Rhinology* 2023;**61**:2–11
- 60 Vaira LA, Lechien JR, Salzano G, Maglito F, Boscolo-Rizzo P, Hopkins C *et al.* SARS-CoV-2 effects on psychophysical olfactory scores: prospective study with evaluation before and 60-days after infection. *Otolaryngol Head Neck Surg* 2023;**168**:1249–52
- 61 Lee DY, Lee WH, Wee JH, Kim JW. Prognosis of postviral olfactory loss: follow-up study for longer than one year. *Am J Rhinol Allergy* 2014;**28**:419–22